We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

192 hedge funds and large institutions have $1.74B invested in Cytokinetics in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 62 increasing their positions, 63 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 17

65% more call options, than puts

Call options by funds: $5.35M | Put options by funds: $3.23M

15% more capital invested

Capital invested by funds: $1.51B → $1.74B (+$224M)

8% more funds holding

Funds holding: 178 → 192 (+14)

2.22% more ownership

Funds ownership: 103.03% → 105.26% (+2.2%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

2% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 63

Holders
192
Holders Change
+14
Holders Change %
+7.87%
% of All Funds
3.37%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
32
Increased
62
Reduced
63
Closed
17
Calls
$5.35M
Puts
$3.23M
Net Calls
+$2.11M
Net Calls Change
-$5.53M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$59.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$33.1M
3
LGM
Logos Global Management
California
+$14.9M
4
CCM
CAAS Capital Management
New York
+$14.3M
5
MWNA
Marshall Wace North America
New York
+$13.5M

Top Sellers

1
BI
BVF Inc
California
-$101M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16.9M
3
PCH
Polar Capital Holdings
United Kingdom
-$12.8M
4
FCMI
Foresite Capital Management IV
California
-$11.8M
5
State Street
State Street
Massachusetts
-$10.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$277M +$6.76M +316,365 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$114M +$1.65M +77,185 +2%
State Street
3
State Street
Massachusetts
$96.3M -$10.7M -498,953 -11%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$89.4M +$59.9M +2,804,132 +270%
DCM
5
Driehaus Capital Management
Illinois
$75.3M +$194K +9,071 +0.3%
MWNA
6
Marshall Wace North America
New York
$62.8M +$13.5M +632,255 +31%
PCH
7
Polar Capital Holdings
United Kingdom
$62.1M -$12.8M -600,000 -18%
WA
8
Wasatch Advisors
Utah
$60.7M +$1.15M +54,011 +2%
DM
9
Deerfield Management
New York
$59.6M +$2.14M +100,000 +4%
FCM
10
Farallon Capital Management
California
$58.1M +$2.14M +100,000 +4%
BC
11
Boxer Capital
California
$48.8M – – –
RI
12
RTW Investments
New York
$46.5M – – –
Adage Capital Partners
13
Adage Capital Partners
Massachusetts
$36.1M +$33.1M +1,550,000 New
PHS
14
PFM Health Sciences
California
$35.7M +$12.1M +565,222 +58%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$26.9M +$2.19M +102,567 +10%
Wellington Management Group
16
Wellington Management Group
Massachusetts
$23.2M -$3.85M -180,518 -15%
Two Sigma Advisers
17
Two Sigma Advisers
New York
$22.7M +$4.72M +221,200 +29%
Millennium Management
18
Millennium Management
New York
$21.4M +$765K +35,821 +4%
BNP Paribas Asset Management
19
BNP Paribas Asset Management
France
$21.1M +$5.8M +271,636 +43%
FCMI
20
Foresite Capital Management IV
California
$20.5M -$11.8M -554,091 -39%
RM
21
RP Management
New York
$20.4M – – –
Northern Trust
22
Northern Trust
Illinois
$18.8M -$582K -27,276 -3%
Goldman Sachs
23
Goldman Sachs
New York
$18.7M -$395K -18,476 -2%
Morgan Stanley
24
Morgan Stanley
New York
$16.4M -$4.09M -191,460 -21%
VC
25
Vivo Capital
California
$16.3M – – –
1
2 3 4 5

CYTK Hedge Fund Activity: Q1 2021 in Review

192 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2021, worth a combined $1.74B — up 15% from $1.51B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new CYTK positions and 17 closed out — a net gain of 15 holders — while 62 added to existing stakes and 63 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $59.9M. The largest seller was BVF Inc, exiting entirely with an estimated $101M sold.

  • 192 institutional investors held Cytokinetics (CYTK) as of Q1 2021, up from 178 in Q4 2020.
  • Funds reported $1.74B of Cytokinetics stock for Q1 2021, up 15% quarter-over-quarter.
  • 32 funds opened new Cytokinetics positions in Q1 2021 and 17 closed out, a net change of +15 holders.
  • The largest Cytokinetics buyer in Q1 2021 was Fidelity Investments, an estimated $59.9M added.
  • The largest Cytokinetics seller in Q1 2021 was BVF Inc, an estimated $101M sold.

Based on aggregated 13F filings for Q1 2021.